Beta Bionics (BBNX) CCO sells shares to cover RSU taxes under 10b5-1 plan

Rhea-AI Filing Summary

Beta Bionics Chief Commercial Officer Mark Hopman sold 2,917 shares of Common Stock in open-market transactions, primarily to cover tax withholding tied to vested restricted stock units. The sales occurred at weighted average prices around $30–31 per share under a pre-arranged Rule 10b5-1 trading plan.

Following these transactions, Hopman directly holds 136,216 shares of Beta Bionics Common Stock, indicating he retains a substantial equity stake in the company.

Insider Trade Summary 10b5-1

Net Seller: 2,917 shares ($88,304)

Net Sell 2 txns

Insider Hopman Mark

Role Chief Commercial Officer

Sold 2,917 shs ($88K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,061	$30.661	$63K
Sale	Common Stock	856	$29.3359	$25K

Holdings After Transaction: Common Stock — 136,216 shares (Direct)

Footnotes (1)

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. The weighted average sale price for the transaction reported was $30.6610 and the range of prices were between $30.02 and $31.0024. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/02/2025		S(1)		856	D	$29.3359	138,277	D
Common Stock	12/04/2025		S(2)		2,061	D	$30.661(3)	136,216	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.

3. The weighted average sale price for the transaction reported was $30.6610 and the range of prices were between $30.02 and $31.0024. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Beta Bionics (BBNX) executive Mark Hopman report in this Form 4?

Mark Hopman reported selling 2,917 shares of Beta Bionics Common Stock. The transactions were open-market sales linked to tax withholding for vested restricted stock units and executed under a pre-arranged Rule 10b5-1 trading plan.

How many Beta Bionics (BBNX) shares does Mark Hopman still own after the sales?

After the reported transactions, Mark Hopman directly holds 136,216 shares of Beta Bionics Common Stock. This post-transaction balance shows he maintains a significant equity position despite selling shares to address tax obligations.

Why did Mark Hopman sell Beta Bionics (BBNX) shares in this filing?

The shares were sold to cover tax withholding obligations from the vesting of restricted stock units. This type of sale is typically mechanical, ensuring required taxes are paid when equity awards vest, rather than reflecting a discretionary portfolio shift.

Were Mark Hopman’s Beta Bionics (BBNX) share sales made under a Rule 10b5-1 plan?

Yes, the filing states the shares were sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025. Such plans pre-schedule transactions, reducing the significance of short-term market timing in these sales.

At what prices did Mark Hopman sell his Beta Bionics (BBNX) shares?

The weighted average sale price for one transaction was $30.6610 per share, with trades between $30.02 and $31.0024. Another sale occurred at an average price of $29.3359 per share, reflecting typical market-price executions.